Research article summary (published 30 Jul 2009):

OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.

Full Abstract

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common behavioral disorders in childhood. It continues into adulthood in up to 65% of patients. Methylphenidate (MPH) is one of the most commonly used pharmacological treatments for ADHD. The osmotic-release oral system (OROS) formulation of MPH is an extended-release pharmaceutical form that delivers MPH in a controlled manner over a 12-h period, allowing management of symptoms for a full day. OROS-MPH has many advantages over immediate-release MPH, such as avoiding clinical rebound, being easy to take, increasing treatment adherence and reducing the risk of abuse. OROS-MPH has been approved in the USA and Europe for the treatment of ADHD in children, but it has only been approved for the treatment of adults in the USA and Canada. This review summarizes evidence from various clinical studies assessing the efficacy and safety of OROS-MPH in different clinical samples of adults with ADHD, including samples with the most common comorbidities found in ADHD patients. The studies are classified according to their design characteristics as randomized, controlled trials or open trials. Data on dosing, treatment adherence and other clinical parameters relevant for the use of OROS-MPH in adults with ADHD are also reported and discussed.

Author information

Author/s: Ramos-Quiroga, J Antoni (JA); Corominas, Margarida (M); Castells, Xavier (X); Bosch, Rosa (R); Casas, Miguel (M);

Affiliation: Adult ADHD Program, Department of Psychiatry, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain. jaramos(-atsign-)vhebron.net

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

Journal: Expert review of neurotherapeutics (Expert Rev Neurother), published in England. (Language: eng)

Reference: 2009-Aug; vol 9 (issue 8) : pp 1121-31

Dates: Created 2009/08/13; Completed 2009/10/26;

PMID: 19673602, status: MEDLINE (last retrieval date: 10/26/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adult Attention Deficit Disorder with Hyperactivity - drug therapy Central Nervous System Stimulants - metabolism; pharmacokinetics; therapeutic use Drug Administration Routes Drug Delivery Systems

Drug Delivery Systems Guidelines as Topic Humans Methylphenidate - chemistry; metabolism; pharmacokinetics; therapeutic use Randomized Controlled Trials as Topic

Associated Chemicals: Central Nervous System Stimulants (0) ; Methylphenidate (113-45-1)

Related articles

These are the highest related articles currently in the database:

• New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. 30 Dec 2003
• Pharmacokinetics and clinical effectiveness of methylphenidate. 29 Nov 1999
• Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. 27 Mar 2007
• Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder. Dec 2007
• Osmotic, controlled-release methylphenidate for the treatment of ADHD. 29 Sep 2006
• An ADHD 6-year-old child ultrarapid metabolizer for CYP2D6. 30 Jul 2006
• Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. 8 Mar 2002
• Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. 29 Jun 2006
• Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. 30 Jul 2008
• An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. 30 Dec 2007

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.